Details
In this request, we investigated utilization patterns of Dupixent (dupilumab). The assessed cohorts differed by inclusion requirement: no inclusion requirement; a diagnosis of eosinophilic esophagitis (EoE) using a narrow definition; a diagnosis of EoE using a broad definition; a diagnosis of other health outcomes including atopic dermatitis, asthma, or chronic rhinosinusitis with nasal polyps; a diagnosis of EoE using the narrow definition and a diagnosis of one of the aforementioned other health outcomes; and a diagnosis of EoE using the broad definition and a diagnosis of one of the aforementioned other health outcomes.
The study period includes data from January 1, 2017 to March 31, 2020.
We executed this request on Merative™ MarketScan® Research Databases on July 23, 2021.